Hepatitis C News

AMSTERDAM — The benefits of both double and triple direct-acting antiviral therapy combinations depend on myriad patient and disease factors, according to findings presented at the International Liver Congress.

AMSTERDAM — In this exclusive video from International Liver Congress, Jason Grebely, PhD, from the Kirby Institute at the University of New South Wales, Sydney, reviews strategies discussed at the conference for enhancing prevention and treatment of hepatitis C among people who inject drugs.

AMSTERDAM — Dealing with hepatitis C virus as a systemic disease, and not just a complication of the liver, may aid clinicians in reducing extrahepatic manifestations of the infection, according to experts at the International Liver Congress.

Hepatitis C incidence among HIV-positive men who have sex with men has shown no significant decline in Europe, though the trends differ by geographical region and age, according to results of a recently published study.

Direct-acting antiviral therapy for hepatitis C was highly effective and well-tolerated in patients aged 65 years and older, resulting in most patients achieving sustained virologic response, according to results of a recent study.

The vast majority of young people with hepatitis C virus infection in the United States live more than 10 miles away from a syringe services program, researchers said.

Researchers compared estimated national costs of direct-acting antiviral therapy between Germany and Australia to clarify what steps may be necessary to achieve the WHO hepatitis C elimination goals, according to a recently published editorial.

Alcohol use disorders contributed to more than two-thirds of liver-related complications in adults discharged with chronic hepatitis C from French hospitals between 2008 and 2013, according to a recently published study.

Community-based treatment with a dedicated primary care program led to sustained virologic response in most homeless and marginally housed patients with hepatitis C enrolled in a recent study.

The WHO prequalified the generic active pharmaceutical ingredient sofosbuvir on Mar. 31, 2017, according to a press release from the organization. This is the first time WHO has prequalified a generic active ingredient for hepatitis C.